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Abstract
Background: In the absence of an effective vaccine, malaria treatment and eradication is still a challenge in most
endemic areas globally. This is especially the case with the current reported emergence of resistance to artemisinin
agents in Southeast Asia. This study therefore explored the prevalence of K13-propeller gene polymorphisms among
Plasmodium falciparum parasites in northern Uganda.
Methods: Adult patients (≥18 years) presenting to out-patients department of Lira and Gulu regional referral hospitals
in northern Uganda were randomly recruited. Laboratory investigation for presence of plasmodium infection among
patients was done using Plasmodium falciparum exclusive rapid diagnostic test, histidine rich protein-2 (HRP2) (Pf).
Finger prick capillary blood from patients with a positive malaria test was spotted on a filter paper Whatman no. 903.
The parasite DNA was extracted using chelex resin method and sequenced for mutations in K13-propeller gene using
Sanger sequencing. PCR DNA sequence products were analyzed using in DNAsp 5.10.01software, data was further
processed in Excel spreadsheet 2007.
Results: A total of 60 parasite DNA samples were sequenced. Polymorphisms in the K13-propeller gene were detected
in four (4) of the 60 parasite DNA samples sequenced. A non-synonymous polymorphism at codon 533 previously
detected in Cambodia was found in the parasite DNA samples analyzed. Polymorphisms at codon 522 (non-synonymous)
and codon 509 (synonymous) were also found in the samples analyzed. The study found evidence of positive selection in
the Plasmodium falciparum population in northern Uganda (Tajima’s D = −1.83205; Fu and Li’s D = −1.82458).
Conclusions: Polymorphism in the K13-propeller gene previously reported in Cambodia has been found in the Ugandan
Plasmodium falciparum parasites. There is need for continuous surveillance for artemisinin resistance gene markers in
the country.
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Background
Malaria is the leading cause of morbidity and mortality
in Uganda accounting for 30–50 % of outpatient visits,
15–20 % of hospital admissions and is responsible for
nearly half of all inpatient pediatric deaths [1]. Uganda
has the third highest number of malaria deaths in Africa
in addition to having the highest reported malaria trans-
mission rates in the world [2]. The country also has a
high (90–95 %), stable and perennial malaria transmis-
sion throughout the year [3]. In Uganda, national policy
for treatment of uncomplicated malaria was first chan-
ged from chloroquine (CQ) monotherapy to CQ plus
sulfadoxine-pyrimethamine (SP) (CQ + SP) combination
therapy in 2000. However this was also changed to the
current artemisinin based combination (ACTs) antimal-
arial agents in 2004 due to wide spread resistance to the
earlier agents [4].
The artemisinin agents are rapidly acting and signifi-
cantly reduce the biomass of sensitive parasites corre-
sponding to a single cycle of a sexual blood stage of
Plasmodium falciparum in 48 h [5]. The use of short
acting artemisinin (half-life <1 h) and long-lasting part-
ner drug (lumefantrine, amodiaquine, or piperaquine)
in artemisinin-based combination therapy (ACTs), has
contributed to an estimated 30 % reduction in global
rate of malaria associated mortality in the past decade
[6]. However, the emergence of artemisinin resistance
in Southeast Asia threatens malaria control and preven-
tion programs globally [7]. With the experience of chloro-
quine resistance in which it resulted in doubling of
malaria associated mortality in sub-Saharan Africa [8], the
emergence of artemisinin resistance [9] could potentially
pose a similar risk especially in malaria endemic areas of
the world.
Artemisinin resistance is currently associated with
polymorphisms in the K13-propeller gene [9]. Genomic
analysis of Cambodian parasite isolates have identified
four prevalent K13-propeller mutations (Y493H, R539T,
I543T, and C580Y) that are associated with elevated
ring-stage survival rates In vitro and long parasite clear-
ance half-lives (>5 h) [10]. Evidence from previous stud-
ies have indicated that artemisinin resistance affects
early ring-stage of the plasmodium parasites’ intraery-
throcytic developmental cycle [11].
The spread of artemisinin resistance to other parts of
the world is quite likely as previous parasite resistance
to chloroquine and sulphadoxine-pyrimethamine all
arose from the same region, Cambodia and spread glo-
bally [12, 13]. This is further indicated by the current
spread of artemisinin resistance in most provinces of
Cambodia, Thailand-Myanmar border, southern Vietnam,
southern Laos and central Myanmar [14]. It thus seems a
matter of time before the K13 gene polymorphisms de-
tected in Cambodia and associated with artemisinin
resistance can spread to parts of the world outside South-
east Asia. With limited or no current alternative medi-
cines to artemisinin agents in addition to lack of an
effective vaccine, the future of malaria treatment is facing
perhaps the greatest test since the emergence of chloro-
quine resistance more than a decade ago.
With increased use of artemisinin based combination
agents in malaria treatment globally [2], surveillance pro-
grams are needed to help monitor the emergence and
spread of resistance. This study was thus intended to inves-
tigate the prevalence of resistance gene markers to artemi-
sinin antimalarial agents among Plasmodium falciparum
parasites isolated from adult patients (≥18 years) reporting
to hospitals in northern Uganda.
Methods
Study design, area and population
This was a cross sectional study done among patients pre-
senting with symptoms of malaria (fever) to Lira and Gulu
regional referral hospitals (RRHs) in northern Uganda.
The two hospitals are more than 300 km from the capital
Kampala and the districts of their location are shown in
the map of Uganda, (Fig. 1).
Sampling criteria
Adult patients (≥18 years) reporting to the general labora-
tory in out-patients department (OPD) with a request
from the doctor for a malaria test were all contacted for
recruitment into the study using the interval of 4 and 3 in
Lira and Gulu regional referral hospitals respectively. Pa-
tients who provided written informed consent were then
recruited into the study.
Laboratory analysis
Sample collection and processing
Data collection was done from August 2013 to May 2014
with blood sample collection occurring between 8 AM
-to- 4 PM on each working day (Monday-to-Friday) dur-
ing the study period. Capillary blood from a finger prick
was collected from each patient after sterilizing the finger-
tip using alcohol swab. The blood was then tested for
presence of plasmodium infection using a Plasmodium
falciparum exclusive rapid diagnostic test, HRP2 (Pf) (Ac-
cess Bio, Inc, USA). The patients with positive result for
Plasmodium falciparum infection were notified and more
capillary blood collected and spotted on a filter paper
Whatman No. 903. Plasmodium parasite DNA was ex-
tracted from the dried blood spots on filter paper using
chelex resin method as previously described by Plowe,
1995 [15]. Polymorphisms at K13-propeller gene of Plas-
modium falciparum parasite was determined using Sanger
sequencing. This was done in the molecular diagnostic
laboratory (MBN Clinical Laboratories Ltd), P. O. Box
35135, Kampala, Uganda (www.mbnlab.com).
Ocan et al. BMC Infectious Diseases  (2016) 16:428 Page 2 of 9
PCR amplification and sequencing of P. falciparum isolates
For amplification of the K13 gene, we used nested PCR
to amplify 849 bp fragment extending from nucleotides
1329-to-2178 (codons 445-to-727) within the entire
K13-propeller domain. The first and second round amp-
lification reactions were performed using a Thermal cy-
cler (Bio-Rad, T100; Singapore) in 25 and 50 μl reaction
volumes respectively. The K13-propeller domain was
amplified using the following primers (Eurofins Genom-
ics, German);
First round PCR (K131-5′CGGAGTGACCAAATCTG
GGA-3′ and
K134-5′-GGGAATCTGGTGGTAACAGC-3′),
Second round PCR (K133-5′-GCCTTGTTGAAAGA
AGCAGA-3′;
K132-5′GCCAAGCTGCCATTCATTTG-3′).
Fig. 1 Map of Uganda showing the districts where the study was conducted in northern Uganda: An updated map of Uganda as provided by the
United Nations Office for the Coordination of Humanitarian Affairs, 2006; based on OCHA/ReliefWeb
Ocan et al. BMC Infectious Diseases  (2016) 16:428 Page 3 of 9
First round PCR was run in a 25 μl reaction volume:
briefly, 5.5 μl of nuclease free water (QIAGEN, Maryland,
USA) was added to 12.5 μl of Taq 2X Master Mix (New
England BioLabs, Massachusetts, USA). We used Taq 2X
Master Mix with the final working concentration of the
components at 1X. The concentration of the components
at 1X were: 10 mM Tris-HCl, 50 mM KCl, 1.5 mM MgCl2,
0.2 mM dNTPs, 25 units/ml Taq DNA Polymerase, 5 %
Glycerol, 0.08 % IGEPAL® CA-630, 0.05 % Tween®,
pH 8.6@25 °C). To this 1.0 μl of 10pmol/μl each of the for-
ward and reverse primers was added. 5.0 μl of 50 ng/μl
DNA template was then added. The PCR was run using
the profile that included Initial denaturation at 94 °C for
5 m, followed by 40 cycles of Denaturation at 94 °C for 30s,
Primer annealing at 54 °C for 90s and Extension at 68 °C
for 90s. Final extension was then done at 68 °C for 10 min.
The products of the first round PCR were used as
templates for the second round PCR. This was run in a
50 μl reaction volume; briefly, 19 μl of nuclease free
water (QIAGEN, Maryland, USA) was added to 25 μl of
Taq 2X Master Mix (New England BioLabs, Massachu-
setts, USA). The final working concentrations of the
components of the Master Mix for the second round
PCR were similar to those of the first round PCR. 2.0 μl
of 10pmol/μl each of the forward and reverse primers
was added. To this mixture was then added 2.0 μl of the
first round PCR amplicons and the PCR reaction run
using the amplification profile as described above.
All PCR products were analyzed using 1 % (w/v) Agar-
ose gel (Fisher Scientific, USA), stained with 0.05 μg/mL
of Ethidium Bromide (Sigma Aldrich, USA).
Sequencing of K13 propeller gene
To sequence the K13 propeller gene, the second round
PCR products were purified using jet quick PCR product
purification kit (Genomed, Cat number 41-0050). 5 μl of
the purified second round PCR products were run on 1.0 %
(w/v) Agarose gel stained with 0.05 μg/mL of Ethidium
Bromide (Sigma Aldrich, USA) to check for the presence
and concentration of PCR products. Bi-directional cycle se-
quencing of K13 was done using second round PCR
primers K133 Forward and K132 Reverse (Eurofins Gen-
omics, Germany), using the BigDye terminator v3.1 cycle
sequencing kit (Applied Bio systems, USA). The cycle se-
quencing PCR was performed in a total reaction volume of
20 μl. Briefly, 6.0 μl of the BigDye terminator v3.1 5X se-
quencing buffer (Applied Bio systems, USA) was aliquoted
and mixed with; 2.0 μl BigDye terminator v3.1 (Applied Bio
systems, USA), 1.0ul of 10 ng/μl (K133Fwd or K132Rev)
primers and 6.0ul of nuclease free water. Then, 5.0ul of
5.0 ng/μl of the purified second round PCR products was
added. The sequencing reactions where run in the Thermal
cycler (Gene Amp 9700 PCR system, USA) under the fol-
lowing conditions. One cycle of Polymerase activation at
96 °C for 60s followed by 35 cycles of; denaturation at
96 °C for 10s, annealing at 53 °C for 30s, extension at
60 °C for 300 s. The products were then stored at 4 °C
until the next step. The Extension (Cycle sequencing) PCR
products were then purified using DyeEx 2.0 spin Kit (QIA-
GEN, Maryland, USA). 5.0 μl of the purified cycle sequen-
cing PCR products were pipetted and mixed with 5.0 μl of
De-ionized formamide (Sigma Aldrich, USA). This mixture
was then loaded in the 310 genetic analyzer (Applied Bio
systems, USA) and the products bi-directional sequenced
with POP-7™ (Applied Bio systems, USA) as a sequencing
Polymer.
Sequence data analysis
The sequence data were base called using the sequence
analysis software 5.2 and then blasted on to the NCBI se-
quence data base to confirm the K13 propeller gene se-
quences identity. The sequences were imported in to bio
edit sequence alignment editor 7.2.5 for manual editing
and then exported in to MEGA 5 software version 5.10
for detection of polymorphism using the PF3D7_1343700
K13-propeller gene sequences in NCBI database as the
reference sequence. Further SNPs analysis within the K13
propeller gene was performed using the DnaSP software
version 5.10.01.
We assessed the selection pressure in Plasmodium fal-
ciparum parasite population in northern Uganda using
Tajima’ D statistic and Fu & Li’s D test in DnaSP soft-
ware 5.10.01. In this analysis we evaluated whether the
P. falciparum K13 propeller domain sequence data
shows evidence of deviation from neutrality theory of
molecular evolution [16]. A total of 60 (sixty) DNA sam-
ple sequence data of P. falciparum parasites from Lira
and Gulu districts were exported directly from Bioedit
into the DnaSP software for computation of Tajima’s D
and Fu & Li’s D statistic. The analysis was done using
commands in the DnaSP software. In DnaSP software,
the probability of Tajima’s D and Fu & Li’s D are esti-
mated by simulation. The test uses information on fre-
quency of mutations (allelic variation) [17]. Tajima’s D
and Fu & Li’s D test is based on the fact that under the
neutral model, estimates of the number of polymorphic
sites and of the average number of nucleotide differences
are correlated. The critical values (Tajima’s D and Fu &
Li’s D) obtained were used in interpreting the findings
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Data was analyzed in Excel spread sheet 2007.
Results
We collected blood samples from a total of 100 patients
with symptomatic Plasmodium falciparum infection
(malaria) who visited out-patient departments of Lira
and Gulu regional referral hospitals (50 patients from
each hospital). The average age of the study participants
was 28 ± 8.7. The study was conducted in the outpatient
department laboratory of Lira and Gulu regional referral
hospitals in northern Uganda. Sixty (60) parasite DNA
samples that successfully amplified in the nested PCR
reaction for K13-propeller gene were all sequenced.
Prevalence of K13 polymorphisms
Single nucleotide polymorphisms (SNPs) found in the
K13-propeller gene include; 509, 522, and 533 (Table 1
and Additional file 1). One of the nonsynonymous SNPs
(533) found in the current study has been previously
reported in Cambodia [9]. Mutation at codon 509 was
found in two samples while others were present in one
sample each.
In total, there were four (4) polymorphic sites identi-
fied in the 60 samples analyzed. The mutations in the
samples analyzed were not selectively neutral as shown
by the negative Tajima’s D statistic (−1.83205) and Fu &
Li’s D test (−1.82458). There was no significant haplo-
type/gene diversity (P = 0.215) with the variance in diver-
sity of 0.0056 and the standard deviation of 0.075
(Table 2).
Discussion
Resistance to the artemisinin agents can be assessed
using both molecular (genotypic) and phenotypic (Ring
Stage survival Assay; RSA0–3hr) methods. Artemisinin re-
sistance mainly manifests as delayed parasite clearance
and is associated with decreased In vitro action of pulses
of artemisinin agents [19, 20] that is associated with
ACT failures [21]. In this study we used molecular para-
site characterization to denote existence or absence of
resistance to artemisinin agents among the Plasmodium
falciparum parasite population in northern Uganda.
In the current study, non-synonymous mutations at
codon 522 and 533 of the K13 propeller gene were de-
tected in the Plasmodium falciparum parasites. The
mutation at codon 533 found in the current study has pre-
viously been reported in Plasmodium falciparum parasites
in Cambodia [9]. The parasites carrying this mutation
were assessed for phenotypic resistance using RSA 0–3h
method, and were shown not to be associated with ar-
temisinin resistance in a study by Ariey et al., [22]. A
study by Feng et al., [23] reported presence of poly-
morphism at codons 537 and 574 of the K13 propeller
gene in Plasmodium falciparum parasites isolated from
Ghanaian migrants to China, mutations previously re-
ported in Cambodia [22]. A mutation at codon 522 found
in our study was also reported in a previous study done in
Uganda by Conrad et al., [24]. However whether these
mutations are associated with Plasmodium falciparum
parasite artemisinin resistance has not been demonstrated.
Recent studies in Uganda have shown artemisinin
agents to be effective in clearing parasites in malaria
treatment [25, 26]. A study by Cooper et al., [27] done
in Uganda failed to demonstrate in an ex vivo assay
using RSA0–3hr method the presence of decreased sen-
sitivity of Plasmodium falciparum parasite isolates to
the artemisinin agents.
The polymorphisms in K13-propeller gene, C580Y,
R539T, R543I and Y493H reported in Cambodia and as-
sociated with artemisinin resistance [9] were not found
in the current study. Our findings in addition to those of
Feng et al., [23] done in Ghana, and other African coun-
tries [28] are indicative of the potential risk of emer-
gence of artemisinin resistance among Plasmodium
falciparum parasites in Sub-Saharan Africa. One muta-
tion at codon position 509 found in our study has not
previously been reported by other studies. Recent studies

















1527 509 GAG GAA G→A Glutamine Glutamine S 3.3 % (n = 2)
1566 522 AGT AGG T→G Serine Arginine NS 1.7 % (n = 1)
1599 533 GGT TGT G→T Glycine Cysteine NS 1.7 % (n = 1)
NS non-synonymous mutation, S synonymous mutation
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done in Uganda [24, 27], Africa [28–30], Myanmar [31]
have also found mutations in malaria parasites not previ-
ously reported in Cambodia [22]. Such geographical var-
iations in the K13-propeller gene mutations is indicative
of the existence of a reservoir for the K13-propeller gene
polymorphisms globally [28]. However whether this
mutations are correlated with reduced parasite clear-
ance in malaria treatment by the artemisinin agents
needs to be elucidated as this would help in tracking ar-
temisinin resistance in malaria endemic areas outside
of Southeast Asia.
Due to high malaria transmission in sub-Saharan Africa,
it is likely that this could result in high use of artemisinin
agents. In Uganda, a study by Ocan et al., [32] found high
prevalence, 29 % of non-prescription use of ACTs (Coar-
tem) in northern Uganda. Uganda adopted a policy on
home based treatment of fever using artemisinin combin-
ation agents [33] and presumptive treatment of all fevers
as malaria [34]. A report by world health organization [2],
also showed a 30-fold increase in the use of ACTs globally
between 2006 and 2013. This increased use of artemisinin
agents is likely to raise drug pressure and hence the risk of
resistance development [35]. In addition, inappropriate
use of artemisinin antimalarial agents coupled with the
risk of using medicines of substandard quality common
in developing countries may further exacerbate the risk
of resistance development [2]. Like chloroquine and
sulfadoxine-pyrimethamine resistance which first emerged
in Southeast Asia then spread to other parts of the world
[36], it is possible that the artemisinin resistance that has
been detected in Cambodia could also spread through
Myanmar via India to Africa [37]. This is likely due to the
increased international travel and migration [38]. When
we tested the departures of nucleotide variability patterns
of the sequence products from neutral expectations using
Tajima’s D and Fu & Li’s D test statistic, there was
evidence of positive selection (or selective sweeps) as
indicated by the negative values of the tests (Tajima’s
D = −1.83205; Fu and Li’s D of −1.82458) [39]. Previous
studies have shown that local ecological and population
level processes such as drug pressure are important
drivers of resistance development in the population
[38–40]. However this study could not establish
whether the K13-propeller gene mutations observed in
the Plasmodium falciparum parasite population in
northern Uganda were as a result of transfer through
global human travel or local emergence as a result of
ecological and population level processes.
Unlike Africa where Artemisinin agents are mostly
used in combinations, studies have shown that up to
78 % of their use in Cambodia are as monotherapy [41].
The basis for artemisinin combination therapy (ACTs) is
that the artemisinin component would rapidly reduce
parasite load in blood, quickly resolve symptoms, and
the partner drug would remain active for days or weeks
and ‘mop up’ any remaining parasites [5]. The use of ar-
temisinin agents in combination coupled with their short
half-lives may still be protecting the population from
wide spread emergence of resistant parasites [42]. How-
ever, Uganda recently also adopted the use of artemisinin
monotherapy (IV artesunate) in treatment of complicated
malaria [43]. The use of Artemisinin agents especially as
monotherapy has been associated with selective pressure
in parasites isolated from French Guyana and Senegal
[44]. A review by Winzeler, [41] also reported failure of
parasite clearance among patients treated with artesunate
monotherapy. Therefore use of artemisinin monotherapy
could potentially enhance the risk of resistance develop-
ment in the country.
Artemisinin agents are used in combination and there-
fore when resistance develops to the artemisinin com-
ponent the other partner drug could be sufficiently
effective in order for the combination to retain its effect-
iveness. However, studies have also reported existence of
resistance to the partner agents commonly used in arte-
misinin combination therapy; amodiaquine, lumefan-
trine, and mefloquine [45, 46]. Therefore development
of resistance to the artemisinin component is a potential
Table 2 Haplotype diversity of K13 propeller domain mutation in the DNA analyzed
K13 analysis parameters Lira Gulu Overall
Sample size 38 22 60
Number of Haplotypes (h) 2 2 4
Haplotype (gene) diversity (Hd) 0.201 0.242 0.215
Variance of Haplotype diversity 0.00728 0.01831 0.00564
Standard Deviation of Haplotype diversity 0.085 0.135 0.075
Number of nucleotide sites analyzed 587 587 587
Nucleotide diversity 0.00287 0.00119 0.00132
Tajima’s D statistic −0.88600 −2.27026 −1.83205 (Not significant; P <0.05)
Fu and Li’s D test statistic −0.33513 −1.9147 −1.82458 (Not significant; P <0.05)
Number of polymorphic sites 2 2 4
Ocan et al. BMC Infectious Diseases  (2016) 16:428 Page 6 of 9
threat to the antimalarial artemisinin combination ther-
apy. Studies in Uganda have not been able to demon-
strate failure of parasite clearance by the artemisinin
combination agents used in malaria treatment [24, 26].
However there are reports of decreasing malaria treat-
ment cure rates by the artemisinin combination antimal-
arial agents in Africa [47] and Asia [48]. Phenotypic and
genotypic findings of previous studies [24, 27] coupled
with those of our current study in addition to the preva-
lent inappropriate use of ACTs in communities [49],
support the need for regular epidemiological surveillance
of resistance to artemisinin agents and the partner drugs
currently used in malaria treatment in Uganda.
Currently there is no known alternative medicine to
artemisinin based antimalarial agents for malaria treat-
ment globally. Therefore the possibility of emergence of
artemisinin resistance is likely to increase the risk of
morbidity and mortality from malaria especially in en-
demic areas of the world. Unfortunately there is no tan-
gible response to the likelihood of artemisinin resistance
development in most malaria endemic countries glo-
bally. This is indicated by the findings of our current
study in which ACTs (Coartem) are easily accessed and
used without prescription in the communities [32]. This
could further exacerbate the risk of resistance develop-
ment in the country.
In most parts of the world other than South East
Asia, artemisinin combination agents remain very ef-
fective antimalarial drugs [50]. In Uganda delayed para-
site clearance of ACTs has not yet been detected in
malaria treatment [51]. Partial host immunity from re-
peated exposure due to high malaria transmission com-
mon in sub-Saharan Africa may be masking the loss of
efficacy to ACTs [52]. A study in Mali showed a correl-
ation between immunity against malaria infection
among patient and fast rates of artemisinin-induced
parasite clearance [53].
Due to either the low parasite load as we did not
quantify parasitaemia during blood sample collection or
poor DNA quality, we could not successfully amplify
Plasmodium falciparum K13-propeller gene from all the
100 extracted parasite DNA samples.
Conclusion
This study showed existence of K13-propeller gene mu-
tations among Plasmodium falciparum parasite popula-
tion in northern Uganda. However the polymorphisms
associated with delayed Plasmodium parasite clearance
by artemisinin agents previously reported in Cambodia
were not found in our study. Regular epidemiological
surveillance of molecular and phenotypic artemisinin
resistance in the country is thus needed. This will help
in tracking the possible development of artemisinin
resistance and could help inform updating of malaria
treatment guidelines.
Additional file
Additional file 1: Nucleotide sequences of Plasmodium falciparum DNA
samples with mutations. This file contains the nucleotide sequences of
the Plasmodium falciparum parasite DNA samples that were found to
have polymorphisms and the wild type strains. (PDF 88 kb)
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